1,5-Benzoxazepin-4(5H)-one, 7-bromo-2,3-dihydro-5-methyl- | 1267443-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 1,5-Benzoxazepin-4(5H)-one, 7-bromo-2,3-dihydro-5-methyl-
• 英文别名: 7-bromo-5-methyl-2,3-dihydro-1,5-benzoxazepin-4-one
• CAS: 1267443-85-5
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.1
• InChiKey: OVUBOJIHIROTFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC AMIDES AS KINASE INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2014125444A1

  公开（公告）日：2014-08-21

  Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

  揭示了具有式（I）的化合物，其中X、Y、Z1、Z2、Z3、Z4、R5、RA、m、A、L和B如本文所定义，并公开了制备和使用这些化合物的方法。
• CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

  公开号：EP3816163A1

  公开（公告）日：2021-05-05

  Provided by the present application are a cell necrosis inhibitor, a preparation method therefor and a use thereof; in particular, provided by the present application is an inhibitor of cell necrosis and/or human receptor-interacting protein 1 kinase (RIP1). The inhibitor has a structure as shown in the following formula I. The compound and a composition comprising same may be used to prevent and/or treat diseases involving cell death and/or inflammation.

  本申请提供了一种细胞坏死抑制剂、其制备方法及其用途；特别是，本申请提供了一种细胞坏死和/或人类受体相互作用蛋白1激酶（RIP1）抑制剂。该抑制剂具有如下式 I 所示的结构。该化合物和包含该化合物的组合物可用于预防和/或治疗涉及细胞死亡和/或炎症的疾病。
• HETEROCYCLIC AMIDES AS KINASE INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP2956452B1

  公开（公告）日：2018-03-21
• [EN] RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME<br/>[FR] COMPOSÉS INHIBITEURS DE RIP1 ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2021046437A1

  公开（公告）日：2021-03-11

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.